Retagliptin

Edit links
Source: Wikipedia, the free encyclopedia.
Retagliptin
Identifiers
  • Methyl 7-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(trifluoromethyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-1-carboxylate
JSmol)
SMILES
  • COC(=O)C1=C2CN(CCN2C(=N1)C(F)(F)F)C(=O)C[C@@H](CC3=CC(=C(C=C3F)F)F)N
  • InChI=1S/C19H18F6N4O3/c1-32-17(31)16-14-8-28(2-3-29(14)18(27-16)19(23,24)25)15(30)6-10(26)4-9-5-12(21)13(22)7-11(9)20/h5,7,10H,2-4,6,8,26H2,1H3/t10-/m1/s1
  • Key:WIIAMRXFUJLYEF-SNVBAGLBSA-N

Retagliptin is a

DPP-4 inhibitor studied for the treatment of type 2 diabetes.[1][2][3]

In 2023, it was approved in China by the National Medical Products Administration for blood glucose control for adult patients with type 2 diabetes.[4]

References

  1. ISSN 1759-9679
    .
  2. PMID 29737094
    .
  3. S2CID 45825587
    .
  4. ^ "Retagliptin Phosphate Tablets Approved for Marketing by NMPA". National Medical Products Administration. 2023-06-28.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Retagliptin&oldid=1292753833"